Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024. In this role, Ms. Heim will lead the Canadian affiliate in its unwavering commitment to helping people affected by rare diseases live longer, healthier lives.
The North Carolina Biotechnology Center’s Piedmont Triad Office is welcoming five new thought leaders to its regional advisory committee. Here are the details.
The North Carolina Biotechnology Center’s Piedmont Triad Office is welcoming five new thought leaders to its regional advisory committee.The new advisory committee members include Ken Russell, Gordon Vail, Ph.D., Eric Muth, Ph.D., Summer McGee, Ph.D., CPH, and Serena Guzman. These new members are from unique backgrounds and experiences, academic expertise and industry perspectives which will guide efforts to grow the region’s life sciences assets. Geoff Foster is the new Vice Chair of the committee. Details about each new member are below.
(2)
These two appointments follow a series of first successful achievements for iBiopsy in 2020 and early 2021.
Median prepares to launch its iBiopsy product development plan, including regulatory aspects, define its go-to-market strategy then expand its iBiopsy operations globally.
Regulatory News:
Thomas Bonnefont (Photo: Median Technologies)
Median Technologies (ALMDT:PA) (Paris:ALMDT) announced today the appointment of Thomas Bonnefont to the newly created position of Chief Operating and Commercial Officer of the iBiopsy Business Unit as well as the appointment of Mike Doherty as Sr. Strategy Advisor, iBiopsy Product Development. They both join Median s executive team. Mike Doherty is based in the US.